Selective publication of antidepressant trials and its influence on apparent efficacy

The New England Journal of Medicine
Erick H TurnerRobert Rosenthal

Abstract

Evidence-based medicine is valuable to the extent that the evidence base is complete and unbiased. Selective publication of clinical trials--and the outcomes within those trials--can lead to unrealistic estimates of drug effectiveness and alter the apparent risk-benefit ratio. We obtained reviews from the Food and Drug Administration (FDA) for studies of 12 antidepressant agents involving 12,564 patients. We conducted a systematic literature search to identify matching publications. For trials that were reported in the literature, we compared the published outcomes with the FDA outcomes. We also compared the effect size derived from the published reports with the effect size derived from the entire FDA data set. Among 74 FDA-registered studies, 31%, accounting for 3449 study participants, were not published. Whether and how the studies were published were associated with the study outcome. A total of 37 studies viewed by the FDA as having positive results were published; 1 study viewed as positive was not published. Studies viewed by the FDA as having negative or questionable results were, with 3 exceptions, either not published (22 studies) or published in a way that, in our opinion, conveyed a positive outcome (11 studies). A...Continue Reading

References

Dec 1, 1987·Controlled Clinical Trials·K DickersinH Smith
Jan 1, 1987·Statistics in Medicine·R J Simes
Sep 1, 1986·Controlled Clinical Trials·R DerSimonian, N Laird
Feb 5, 1998·JAMA : the Journal of the American Medical Association·J P Ioannidis
Jul 24, 1998·BMJ : British Medical Journal·N HagdrupY Carter
Mar 31, 2001·The Medical Journal of Australia·J C CraigM R Stockler
Oct 26, 2002·Critical Care : the Official Journal of the Critical Care Forum·Elise Whitley, Jonathan Ball
May 27, 2004·JAMA : the Journal of the American Medical Association·An-Wen ChanDouglas G Altman
Sep 29, 2004·CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne·An-Wen ChanDouglas G Altman
Oct 8, 2004·The New England Journal of Medicine·Eric J Topol
Nov 25, 2004·PLoS Medicine·Erick H Turner
Jan 14, 2005·Personality and Social Psychology Review : an Official Journal of the Society for Personality and Social Psychology, Inc·N L Kerr
Apr 21, 2005·JAMA : the Journal of the American Medical Association·Jonathan D Sackner-BernsteinKeith Aaronson
Jul 21, 2005·Journal of the National Cancer Institute·Panayiotis A KyzasJohn P A Ioannidis
Oct 22, 2005·JAMA : the Journal of the American Medical Association·Steven E NissenEric J Topol
Nov 9, 2005·Journal of Epidemiology·Yasuaki HayashinoTsuguya Fukui
Sep 16, 2006·BMJ : British Medical Journal·Joseph LauIngram Olkin
Apr 11, 2007·CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne·John P A Ioannidis, Thomas A Trikalinos
May 23, 2007·The New England Journal of Medicine·Steven E Nissen, Kathy Wolski

❮ Previous
Next ❯

Citations

Jan 7, 2010·JAMA : the Journal of the American Medical Association·Jay C FournierJan Fawcett
Apr 4, 2009·Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz·G AntesM Schumacher
Jan 20, 2011·Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz·M RoseB Löwe
Oct 18, 2011·Der Nervenarzt·S LeuchtJ M Davis
Feb 2, 2013·Der Nervenarzt·H Schauenburg, T Bschor
Feb 23, 2011·Der Urologe. Ausg. A·F KunathB Wullich
Nov 1, 2011·Diabetologia·M Kivimäki, G D Batty
May 28, 2008·Psychopharmacology·Nick Freemantle
Jul 11, 2009·European Journal of Clinical Pharmacology·C Pandolfini, M Bonati
May 10, 2011·European Journal of Clinical Pharmacology·Alberto ParabiaghiAlessandro Nobili
Oct 22, 2011·European Journal of Clinical Pharmacology·Roser LlopJoan-Ramon Laporte
Jul 14, 2012·European Journal of Nuclear Medicine and Molecular Imaging·Marianne I Martić-KehlP August Schubiger
Nov 21, 2008·European Archives of Psychiatry and Clinical Neuroscience·Hans Jürgen Möller
Nov 27, 2009·European Archives of Psychiatry and Clinical Neuroscience·Wolfgang Maier, Hans-Jürgen Möller
Oct 20, 2009·European Archives of Psychiatry and Clinical Neuroscience·Hans-Jürgen Möller, Wolfgang Maier
Oct 29, 2011·European Archives of Psychiatry and Clinical Neuroscience·Thomas C BaghaiUNKNOWN Section of Pharmacopsychiatry, World Psychiatric Association
May 31, 2008·Administration and Policy in Mental Health·Cathaleene MaciasPaul B Gold
May 25, 2012·Journal of Computer-aided Molecular Design·A Geoffrey Skillman
Dec 24, 2008·Journal of Clinical Psychology in Medical Settings·David Antonuccio
Jul 31, 2013·Journal of General Internal Medicine·Barbara MintzesGeneviève Durrieu
Mar 20, 2010·Internal and Emergency Medicine·Ana MacuraAlfonso Iorio
Nov 5, 2008·Current Psychiatry Reports·Michael E Thase
Sep 22, 2012·Current Psychiatry Reports·James W Murrough, Dennis S Charney
Mar 21, 2013·PharmacoEconomics·Ifigeneia MavranezouliTim Kendall
Sep 1, 2009·Otolaryngology--head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery·Neil Bhattacharyya, Harrison W Lin
Dec 9, 2008·Lancet·Peter Tyrer, Tim Kendall
Jan 15, 2014·Lancet·An-Wen ChanH Bart van der Worp
Oct 1, 2010·International Psychogeriatrics·Osvaldo P AlmeidaJon Pfaff
Oct 23, 2012·International Psychogeriatrics·Dallas P SeitzDavid K Conn
Jul 1, 2011·Epidemiology and Psychiatric Sciences·C TrespidiA Cipriani
Sep 20, 2011·Epidemiology and Psychiatric Sciences·A CiprianiC Barbui
May 12, 2009·Nature Biotechnology·Jim Kling
Jul 14, 2010·Nature Biotechnology·Virginia Hughes

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.